WorldWideScience

Sample records for cevre radyasyonu oelcuemleri

  1. Arc saw development report

    International Nuclear Information System (INIS)

    The arc saw is one of the key components of the Contaminated Equipment Volume Reduction (CEVR) Program. This report describes the progress of the arc saw from its inception to its current developmental status. History of the arc saw and early contributors are discussed. Particular features of the arc saw and their advantages for CEVR are detailed. Development of the arc saw including theory of operation, pertinent experimental results, plans for the large arc saw and advanced control systems are covered. Associated topics such as potential applications for the arc saw and other arc saw installations in the world is also touched upon

  2. GÜNE? ENERJYLY SU ISITMA SYSTEMLERYNDE ISI BORUSU VE VAKUM TÜPÜ KULLANIMININ KARABÜK ?ARTLARINDA DENEYSEL OLARAK YNCELENMESY

    OpenAIRE

    GÜREL, Ali Etem; CAMUR, Dogu; Ergün, Alper

    2010-01-01

    Bu çaly?mada, güne? enerjili su ysytma sistemlerinde ysy borusu ve vakum tüpü uygulamalarynyn kar?yla?tyrylmasy amacyyla, toplam 0.7 m² yüzey alanyna sahip bir kollektör e?it iki bölüme ayrylarak bir kysmyna vakum tüpü, bir kysmyna ise tarafymyzdan imal edilen ysy borusu yerle?tirilmi? ve her iki uygulama 10 litre su hacmine sahip depolara monte edilmi?tir. Be? gün boyunca sistemlere ait güne? radyasyonu, depo suyu sycaklyklary ve dy? sycaklyk de?erleri kaydedilmi?tir. Bu veriler do?rultusun...

  3. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China

    Directory of Open Access Journals (Sweden)

    Wangxia Tong

    2016-01-01

    Full Text Available Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin. Primary outcome was SVR by intention-to-treat analysis. Secondary outcome was RVR, cEVR, ETR, and relapse rate. Results. SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, p=0.812 and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, p=0.014. ETR (98.9% versus 90.6%, p=0.016, virological response at month 3 of end-of- treatment (88.8% versus 76.6%, p=0.044, SVR (80.9% versus 65.6%, p=0.032, and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, p=0.04 in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks. Conclusion. SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks.

  4. Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China

    Science.gov (United States)

    Tong, Wangxia; Zhu, Jianyun; Luo, Ning; Yang, Xiaohua; Lei, Zhiying; Huang, Xiaoliang; Zhao, Zhixin; Zhang, Xiaohong; Gao, Zhiliang; Jiang, Zhonghua

    2016-01-01

    Aim. Our aim is to survey the treatment effect of PEG-IFN plus ribavirin in patients infected with HCV genotype 6a in Guangdong and Guangxi province of China and investigate best course of antiviral treatment for patients with HCV-6a infection. Methods. 515 eligible patients received subcutaneous 180 μg PEG-IFNα-2a or 1.5 μg/kg PEG-IFNα-2b once weekly plus oral ribavirin. Primary outcome was SVR by intention-to-treat analysis. Secondary outcome was RVR, cEVR, ETR, and relapse rate. Results. SVR in patients with HCV-6a infection treated for 48 weeks was comparable to that in patients with HCV-2/3 infection (80.9% versus 82.5%, p = 0.812) and higher than that in patients with HCV-1b infection (80.9% versus 67.2%, p = 0.014). ETR (98.9% versus 90.6%, p = 0.016), virological response at month 3 of end-of- treatment (88.8% versus 76.6%, p = 0.044), SVR (80.9% versus 65.6%, p = 0.032), and virological response at month 12 of end-of-treatment (76.4% versus 60.9%, p = 0.04) in patients with HCV-6a infection treated for 48 weeks were higher than those in patients with HCV-6a infection treated for 24 weeks. Conclusion. SVR in patients with HCV-6a treated for 48 weeks was comparable to that in patients with HCV-2/3 infection and higher than that in patients with HCV-1b infection; patients with HCV-6a infection treated for 48 weeks had a superior treatment response than patients treated for 24 weeks. PMID:27034655

  5. 12例丙型肝炎肝硬化患者脾切除术后抗病毒治疗的临床分析%Clinical features of antiviral therapy in 12 patients with hepatitis C virus-related cirrhosis after splenectomy

    Institute of Scientific and Technical Information of China (English)

    马丽娜; 何智敏; 画伟; 陈新月

    2013-01-01

    Objective To evaluate the therapeutic effects and influencing factors of common antiviral therapy (low-dose interferon plus ribavirin,IFN+RBV) in patients with hepatitis C virus (HCV)-decompensated cirrhosis following splenectomy.Methods Twelve patients were treated postsurgery with low-dose IFN (300-500 MIU QOD) or pegylated (Peg)-IFN (50 μg/w) and RBV (0.6-0.9 g/d) for 72 weeks if carrying the 1b genotype or 48 weeks if carrying the 2a genotype.All patients were followed-up for 24 weeks after treatment completion to determine the virological response (VR)rates,measured as rapid (R)VR,complete early (cE)VR,24 hr (24)VR,and sustained (S)VR.Statistical comparisons were made using the t-test or rank sum test,and correlation analyses were made using the Chi-square test.Differences were considered significant at P < 0.05.Results All 12 patients completed the treatment course and follow-up.Three patients could not tolerate the Peg-IFN and were switched to IFN,and six patients developed hemolysis that required RBV dose adjustment.The VR rates were:25.0%,RVR; 50.0%,cEVR; 16.7%,24VR; 86.0%,SVR.Only one patient was a non-responder,and only one relapsed.Of the patients who achieved SVR,100% had shown RVR,83.3% showed cEVR,and 50.0% showed 24VR,suggesting that RVR and cEVR may effectively predict SVR.Conclusion Some HCV-decompensated cirrhosis patients may benefìt from antiviral therapy following surgical resolution of hypersplenism.The occurrence of RVR and cEVR in these patients is positively correlated with achieving SVR.Physician-patient communication during early antiviral treatment and close clinical monitoring accompanied by psychological counseling throughout promotes success of the treatment approach.%目的 对部分符合外科脾切除术指征且有治疗意愿的失代偿期丙型肝炎肝硬化患者行脾切除术后给予小剂量干扰素联合利巴韦林抗病毒治疗,观察其疗效,并分析与疗效相关的可能影响因素.

  6. 慢性丙型肝炎个体化治疗方案的临床研究%Study of using an individualized treatment strategy to treat patients with chronic hepatitis C

    Institute of Scientific and Technical Information of China (English)

    南月敏; 郑欢伟; 孙殿兴; 安春绵; 李友生; 孔丽; 戴二黑; 张玉果; 赵素贤

    2013-01-01

    Objective To investigate the outcomes of chronic hepatitis C (CHC) patients treated with antiviral regimens of interferon (IFN) plus ribavirin (RBV) using individualized doses and durations.Methods This study was designed as an open-label,prospective clinical trial to analyze the virological responses of 169 CHC patients who received individualized dosages of IFNα-2b or pegylated (Peg)IFNα-2a combined with RBV based on their weight (< 60 kg or ≥ 60 kg),age (< 65 years or 65-75 years),morbid state (liver cirrhosis or not),and complications (such as heart disease,diabetes,thyroid disorder).Treatment duration was calculated using the time required to induce HCV RNA negativity.The rates of virological response and adverse effects among the different groups were compared.Results The IFNα-2b treatment was given to 116 patients,and PegIFNα-2a was given to 53 patients.Compared to the IFNα-2b group,the PegIFNα-2a group showed significantly higher rates of complete early virological response (cEVR; 76.7% vs.92.5%,P < 0.05) and sustained virological response (SVR; 53.6% vs.92.3%,P < 0.05) among the patients who had completed their course of treatment;the rapid virological response (RVR) rate was also higher for the PegIFNα-2a group but the difference did not reach statistical significance (48.7% vs.60.4%,P> 0.05).Seventy-eight patients received the routine dose,and 91 patients received the low dose; there were no significant differences between these two groups for RVR (53.8% vs.58.9%,P> 0.05),cEVR (78.0% vs.80.8%,P> 0.05),or SVR (65.5% vs.58.3%,P> 0.05).Conclusion Use of an individualized antiviral treatment strategy designed according to the patient's baseline condition,early viral kinetics,and tolerability to adverse reactions can achieve a high rate of SVR,as well as improve the safety,prognosis,and cost-effectiveness associated with treating CHC patients.%目的 探讨适于我国丙型肝炎病毒(HCV)慢性感染不